home / press / releases

Menu
  • Search all tables

releases: https://www.cotton.senate.gov/news/press-releases/cotton-introduces-bill-to-codify-successes-of-operation-warp-speed-prepare-for-future-pandemics

One row per release. Full-text search runs over title + body text.

Data license: MIT · Data source: dwillis/congress-press

This data as json

url title date year month party chamber state member_name bioguide_id domain scraper source date_source text has_text collected_at updated_at
https://www.cotton.senate.gov/news/press-releases/cotton-introduces-bill-to-codify-successes-of-operation-warp-speed-prepare-for-future-pandemics Cotton Introduces Bill to Codify Successes of Operation Warp Speed, Prepare for Future Pandemics 2021-05-19 2021 2021-05 Republican Senate AR Tom Cotton C001095 www.cotton.senate.gov cotton https://www.cotton.senate.gov/news/press-releases scraper FOR IMMEDIATE RELEASEContact: James Arnold or Mary Collins Atkinson (202) 224-2353 May 19, 2021 Cotton Introduces Bill to Codify Successes of Operation Warp Speed, Prepare for Future Pandemics Washington, D.C. – Senator Tom Cotton (R-Arkansas) introduced the Operation Warp Speed Act, legislation to codify the successes of Operation Warp Speed for use in the event of another pandemic. The bill addresses shortages in the Strategic National Stockpile, increases the speed of safe approval for life-saving medicine, and improves domestic manufacturing. For bill text, click here. “Operation Warp Speed’s success shouldn’t be ignored—it should be standardized so that the United States is more prepared next time. My bill builds upon the success of Operation Warp Speed and strengthens our ability to fight any future pandemic.” The Operation Warp Speed Act would: Require HHS to assess what supplies are missing from the Strategic National Stockpile, and submit an annual report to Congress on potential production shortfalls in an emergency Give priority to domestic manufacturers for vaccine production and supplies needed for the National Strategic Stockpile Remove emergency use authorization (EUA) approval from the bureaucrats at the FDA and instead allow leaders from the Office of the Assistant Secretary for Preparedness and Response (ASPR), CDC, FDA, NIH to grant EUA approval when three of the four agency leaders agree it is in the country’s best interest, and require these agencies to review EUA data on a rolling basis Assess geographic gaps in clinical trial sites across the United States Grant ASPR flexibility for funds used to secure contracts with the private sector during a public health emergency, and create a new operations role within ASPR to ensure the timely development of vaccines, therapeutics, and diagnostics in the event of another public health emergency. 1 2026-03-30T01:40:41Z 2026-04-06T19:49:40Z
Powered by Datasette · Queries took 0.669ms · Data license: MIT · Data source: dwillis/congress-press